Procaterol
Procaterol is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
HCPCS
No data
Clinical
Clinical Trials
54 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | 5 | 5 | 19 | 5 | 2 | 36 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | 2 | 2 | 3 | 9 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | 2 | 3 | 2 | 7 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | 2 | 2 | 2 | 7 |
| Respiratory aspiration | D053120 | EFO_1001839 | — | — | — | — | 1 | 2 | 3 |
| Cough | D003371 | HP_0012735 | R05 | — | — | — | 1 | 1 | 2 |
| Emergencies | D004630 | — | — | — | — | 1 | 1 | — | 2 |
| Cough-variant asthma | D000096823 | — | — | — | — | — | 1 | — | 1 |
| Nicotiana | D014026 | NCBITaxon_4097 | — | — | — | — | 1 | — | 1 |
| Anaphylaxis | D000707 | — | T88.6 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis | D065631 | — | J30.9 | — | — | 1 | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | — | 1 | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | — | 1 | — | — | 1 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | 1 | — | — | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dyskinesias | D020820 | HP_0002310 | G24 | 1 | — | — | — | — | 1 |
| Ciliary motility disorders | D002925 | EFO_0003900 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | — | — | 2 | 2 |
| Fibrosis | D005355 | — | — | — | — | — | — | 1 | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | — | — | — | 1 | 1 |
| Alpha 1-antitrypsin deficiency | D019896 | — | E88.01 | — | — | — | — | 1 | 1 |
| Argininosuccinic aciduria | D056807 | — | — | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
| Status asthmaticus | D013224 | — | — | — | — | — | — | 1 | 1 |
| Chronic cough | D000096822 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Procaterol |
| INN | procaterol |
| Description | Procaterol is an intermediate-acting β2 adrenoreceptor agonist used for the treatment of asthma. It has never been filed for FDA evaluation in the United States, where it is not marketed. The drug is readily oxidized in the presence of moisture and air, making it unsuitable for therapeutic use by inhalation. Pharmaceutical company Parke-Davis/Warner-Lambert researched a stabilizer to prevent oxidation, but an effective one was never developed.
|
| Classification | Small molecule |
| Drug class | bronchodilators (phenethylamine derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12 |
Identifiers
| PDB | — |
| CAS-ID | 72332-33-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL160519 |
| ChEBI ID | — |
| PubChem CID | 688561 |
| DrugBank | — |
| UNII ID | X7I3EMM5K0 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 547 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
130 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use